Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$2.25B |
| 2 |
Carrier Global
CARR
|
+$938M |
| 3 |
Chevron
CVX
|
+$925M |
| 4 |
Philip Morris
PM
|
+$912M |
| 5 |
Comcast
CMCSA
|
+$899M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$5.31B |
| 2 |
Netflix
NFLX
|
+$1.62B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.48B |
| 4 |
Lockheed Martin
LMT
|
+$781M |
| 5 |
Abbott
ABT
|
+$764M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.46% |
| 2 | Technology | 19.55% |
| 3 | Communication Services | 14.69% |
| 4 | Consumer Discretionary | 11.53% |
| 5 | Industrials | 7.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Aptiv
APTV
$10B
| $372M | 0.12% |
+4,778,622
| New | +$329M |
|
152
Vertex Pharmaceuticals
VRTX
$133B
| $363M | 0.11% |
1,250,659
-5
| -0% | -$1.36K |
|
153
Ryanair
RYAAY
$30.8B
| $358M | 0.11% |
13,474,868
+4,057,440
| +43% | +$103M |
|
154
Haemonetics
HAE
$4.16B
| $357M | 0.11% |
3,988,003
+1,094,203
| +38% | +$111M |
|
155
Texas Instruments
TXN
$254B
| $356M | 0.11% |
2,805,474
-237
| -0% | -$27.6K |
|
|
IPHI
156
DELISTED
INPHI CORPORATION
IPHI
| $354M | 0.11% |
3,015,074
+376,649
| +14% | +$39.6M |
|
157
NVR
NVR
$17B
| $345M | 0.11% |
105,815
+23,753
| +29% | +$72.8M |
|
158
Helen of Troy
HELE
$704M
| $334M | 0.11% |
1,770,286
+102,683
| +6% | +$16.8M |
|
159
Kroger
KR
$34.8B
| $333M | 0.11% |
9,850,839
-6,615,336
| -40% | -$215M |
|
160
Bank of Montreal
BMO
$128B
| $333M | 0.11% |
6,252,421
-1,230,723
| -16% | -$62.8M |
|
|
K
161
DELISTED
Kellanova
K
| $324M | 0.1% |
5,227,736
+149,894
| +3% | +$9.07M |
|
162
Cannae Holdings
CNNE
$670M
| $310M | 0.1% |
7,540,077
+746,520
| +11% | +$25.5M |
|
|
PRAH
163
DELISTED
PRA Health Sciences, Inc.
PRAH
| $309M | 0.1% |
3,176,092
-129,195
| -4% | -$12M |
|
164
Johnson & Johnson
JNJ
$630B
| $303M | 0.1% |
2,156,551
-50,725
| -2% | -$7.39M |
|
165
CMS Energy
CMS
$22.1B
| $301M | 0.1% |
5,160,457
+2,072,090
| +67% | +$120M |
|
|
NBL
166
DELISTED
Noble Energy, Inc.
NBL
| $301M | 0.1% |
33,550,545
+5,572,302
| +20% | +$49.8M |
|
167
Centene
CNC
$33B
| $300M | 0.09% |
4,720,505
-2,451,410
| -34% | -$160M |
|
168
DraftKings
DKNG
$12.5B
| $290M | 0.09% |
+9,152,440
| New | +$253M |
|
|
COUP
169
DELISTED
Coupa Software Incorporated
COUP
| $283M | 0.09% |
1,022,401
+855,843
| +514% | +$172M |
|
|
PXD
170
DELISTED
Pioneer Natural Resource Co.
PXD
| $280M | 0.09% |
+2,863,047
| New | +$252M |
|
171
Arch Capital
ACGL
$33.2B
| $279M | 0.09% |
9,752,870
+391
| +0% | +$10.8K |
|
|
OPTU
172
Optimum Communications Inc
OPTU
$228M
| $278M | 0.09% |
12,351,709
+952
| +0% | +$23.3K |
|
173
Citigroup
C
$231B
| $278M | 0.09% |
5,432,559
+5,092,559
| +1,498% | +$242M |
|
174
McCormick & Company Non-Voting
MKC
$14.5B
| $274M | 0.09% |
3,055,336
+1,242,864
| +69% | +$102M |
|
175
BWX Technologies
BWXT
$15.4B
| $274M | 0.09% |
4,837,268
-425,353
| -8% | -$23.8M |
|
Similar funds
Capital Research Global Investors's Q2 2020 Portfolio in Review
As of Q2 2020, Capital Research Global Investors held 437 positions worth $316B, up 24% from $255B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Capital Research Global Investors's Q2 2020 filing shows 40 new, 173 increased, 147 reduced and 38 closed positions. Its largest new stake was Carrier Global: 50,455,664 shares worth $1.12B. The largest sale was Alibaba, an estimated $5.31B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Technology and Communication Services.
- Capital Research Global Investors's largest Q2 2020 buy was Carrier Global: 50,455,664 shares worth $1.12B.
- Capital Research Global Investors added most to Gilead Sciences in Q2 2020, an estimated $2.25B increase.
- Capital Research Global Investors's biggest Q2 2020 reduction was Alibaba, cutting an estimated $5.31B.
- Capital Research Global Investors fully exited The Stars Group Inc. in Q2 2020, selling an estimated $330M.
- Capital Research Global Investors's ten largest holdings make up 34% of its $316B portfolio in Q2 2020.
- Capital Research Global Investors opened 40 new positions and closed 38 in Q2 2020.
- Capital Research Global Investors's portfolio value rose 24% quarter-over-quarter to $316B.
Based on Capital Research Global Investors's 13F filing for Q2 2020, filed 14 Aug 2020.